EV-201 is an ongoing single-arm, single-agent phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a checkpoint inhibitor.
The first cohort, 120 patients at multiple centers, includes those who had also been treated with a platinum chemotherapy and the second cohort, currently enrolling, includes those who were cisplatin ineligible/platinum naïve. The primary endpoint is confirmed objective response rate, per independent review.
Seattle Genetics said the EV-301 trial is a global, randomized phase 3 clinical trial evaluating enfortumab vedotin versus physician's choice of chemotherapy in approximately 550 patients with previously treated locally advanced or metastatic urothelial cancer.
The EV-301 trial is intended to support a broader global registration strategy and to serve as the confirmatory randomized trial in the US for EV-201.
Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) composed of an anti-Nectin-4 monoclonal antibody attached to a microtubule-disrupting agent, MMAE, using Seattle Genetics' proprietary, linker technology. Enfortumab vedotin targets Nectin-4, a cell adhesion molecule identified as an ADC target by Astellas, which is expressed on many solid tumors.
Seattle Genetics develops and commercializes novel antibody-based therapies for the treatment of cancer. The company's antibody-drug conjugate technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.
Astellas Pharma is dedicated to providing innovative and reliable pharmaceutical products with urology, oncology, immunology, nephrology, and neuroscience as prioritized therapeutic areas, while advancing new therapeutic areas and discovery research leveraging new technologies/modalities.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval